Lexitas Pharma Services
Lexitas Pharma Services is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
Sponsor Glaukos Corp.
- Start (EU)
- Latest update
- Estimated end
A phase 2, double-masked, randomized, multicenter, parallel group, placebo-controlled study to investigate the efficacy and safety of GAL-101, 2%, ophthalmic solution in patients with non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration: eDREAM study
Sponsor Galimedix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants with Phenylketonuria
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Lexitas Pharma Services?
The 2026-10-09 snapshot links Lexitas Pharma Services to 3 distinct CTIS trials. Recorded services include Project management, Clinical monitoring, Ophthalmic central reader, Regulatory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Lexitas Pharma Services?
The most frequently recorded therapeutic areas are Ophthalmology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Lexitas Pharma Services conducted?
The linked trials record locations in 8 countries, including Germany, France, Italy, Spain, Czechia. These are trial locations, not confirmed office locations or countries where Lexitas Pharma Services delivered services.
What can this page tell me about Lexitas Pharma Services's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Lexitas Pharma Services. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Lexitas Pharma Services Inc.
- Lexitas Pharma Services, Inc.